The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination

Pinot de Mora, 2005, Varicella zoster virus vaccination policies and surveillance strategies in Europe, Eurosurveillance, 10, 3, 10.2807/esm.10.01.00511-en

Rentier, 2004, Consensus: varicella vaccination of healthy children, Pediatr Infect Dis J, 23, 379, 10.1097/01.inf.0000122606.88429.8f

Abbink F, Oomen PJ, Zwakhals SLN, Melker HE de, Ambler-Huiskes A. Immunization coverage in The Netherlands as at 1 January 2004. RIVM-report 210021003. The Netherlands; 2005 [In Dutch].

de Melker, 2000, Non-participation in a population-based seroprevalence study of vaccine-preventable diseases, Epidemiol Infect, 124, 255, 10.1017/S0950268899003234

Cochran, 1977

Bartelds, 2003

Aebi, 2001, Age-specific seroprevalence to varicella zoster virus: study in Swiss children and analysis of European data, Vaccine, 19, 3097, 10.1016/S0264-410X(01)00035-4

Gidding, 2003, The seroepidemiology and transmission of varicella in Australia, Epidemiol Infect, 131, 1085, 10.1017/S0950268803001134

Gabutti, 2001, The seroepidemiology of varicella in Italy, Epidemiol Infect, 126, 433, 10.1017/S0950268801005398

Munoz, 2001, Estimated varicella incidence on the basis of seroprevalence survey, Epidemiol Infect, 127, 501, 10.1017/S0950268801006264

Wutzler, 2002, Seroprevalence of varicella zoster virus in the German population, Vaccine, 20, 121, 10.1016/S0264-410X(01)00276-6

Salleras, 2001, Seroepidemiology of varicella zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes, Vaccine, 19, 183, 10.1016/S0264-410X(00)00178-X

Bramley, 2000, Epidemiology of chickenpox in Scotland: 1981–1998, Commun Dis Public Health, 3, 282

Fleming, 2001, The incidence of chickenpox in the community, Eur J Epidemiol, 17, 1023, 10.1023/A:1020066806544

Brisson, 2001, Epidemiology of varicella zoster virus infection in Canada and the United Kingdom, Epidemiol Infect, 127, 305, 10.1017/S0950268801005921

Gil, 2004, The burden of severe varicella in Spain, 1995–2000 period, Eur J Epidemiol, 19, 699, 10.1023/B:EJEP.0000036791.43264.84

Kudesia, 2002, Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy, J Clin Pathol, 55, 154, 10.1136/jcp.55.2.154

Gershon, 2004, Varicella vaccine, 783

Heininger, 2001, Seroprevalence of varicella zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity, Pediatr Infect Dis J, 20, 775, 10.1097/00006454-200108000-00011

Gil, 1998, Prevalence of antibodies against varicella zoster, herpes simplex (Types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents, J Infect, 36, 53, 10.1016/S0163-4453(98)93126-7

van Bovenkamp, 2005, Twijfels over kindervaccinaties. Betere voorlichting zal het draagvlak versterken, Med Contact, 60, 18

Chapman, 2003, The incidence of shingles and its implications for vaccination policy, Vaccine, 21, 2541, 10.1016/S0264-410X(03)00034-3

Postma, 2004, Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations, Eur J Health Econ, 5, 54, 10.1007/s10198-003-0201-6

Thiry, 2003, Economic evaluations of varicella vaccination programmes, Pharmacoeconomics, 21, 13, 10.2165/00019053-200321010-00002

Niessen, 2000, Calculation of costs and cost-effectiveness of stroke units and of secundary prevention in patients after a stroke, as recommended in the revised CBO guideline ‘Stroke’, NTVG, 144, 1959

Oxman, 2005, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med, 352, 2271, 10.1056/NEJMoa051016

Edmunds, 2001, The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales, Vaccine, 19, 3076, 10.1016/S0264-410X(01)00044-5